Please login to the form below

Not currently logged in
Email:
Password:

Sanofi SVP to become president and CEO of Teva Europe

Dr Rob Koremans will take over from Dr Gerard van Odijk

Rob Koremans - Teva EuropeSenior vice president, generic strategy and development, at Sanofi, Dr Rob Koremans, has been appointed president and CEO of Teva Europe.

Koremans will begin his new position in March 2012, when he will take over from Dr Gerard van Odijk who has held both positions for six years.

Van Odijk will remain with the company for the rest of 2012 to help with the transition.

Shlomo Yanai, who is to step down from his current position of president and CEO of Teva Pharmaceutical in May, commented on the announcement.

He said: “Under [van Odijk's] management, our business in Europe has been transformed as Teva became the undisputed generics leader in this major and growing market and established a strong position in speciality pharmaceuticals.

“I am very confident that Rob Koremans, together with our strong European management, will continue our success story across Europe.”

Prior to his current position at Sanofi, Koremans was CEO at Zentiva, the European generics business for Sanofi.

He has also been CEO of Cryo-Save, the stem cell storage company, and was vice president, Europe, of the Serono Group.

4th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics